SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is attracting significant attention as the community debates its recent partnership with Anduril Industries to develop the 'Thunder' autonomous VTOL platform. While some investors view the collaboration as a strategic move into defense applications and a potential catalyst for future growth, others remain cautious due to ongoing share price volatility and the company's progress toward achieving piloted transition flights.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is experiencing significant investor attention following the full commercialization of its massive Beacon Point data center campus, a development that has reinforced the company's transition into a key AI infrastructure player. The community is actively debating the stock's fundamental valuation and sustainability, with many discussing whether recent contract news and hyperscaler demand will drive further momentum despite ongoing market volatility.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is drawing intense community focus as traders debate whether the stock is an undervalued turnaround play following strong June delivery numbers and new contract wins, or a 'value trap' weighed down by persistent production challenges. Investors remain sharply divided, with bulls pointing to the massive order backlog and potential for rising free cash flow, while vocal bears continue to highlight historical underperformance and lack of communication from leadership.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing a significant rebound after announcing a $2.8 billion contract expansion and a raised revenue target, fueling bullish sentiment despite recent volatility. Community members are actively debating the potential for a short squeeze, citing high short interest and the company's shift toward a more capital-efficient model with upfront customer payments.

Phoenix Asia Holdings Ltd. engages in the substructure works and other construction services. It offers site formation, ground investigation and foundation work through it subsidiary. The company was founded on August 9, 2024 and is headquartered in Hong Kong.

Phoenix Asia Holdings Ltd.

Phoenix Asia Holdings is surging due to a definitive agreement to acquire ACEA Pharma in a significant all-stock deal, fueling intense speculation of a potential short squeeze. Community discussion is dominated by the stock's low float and high cost-to-borrow, with retail traders aggressively debating whether the momentum will sustain towards triple-digit targets or result in a sharp reversal.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis (PSNL) is trending due to the definitive agreement to be acquired by Tempus AI in an all-stock deal valued at approximately $1.5 billion, or $16.25 per share. Community discussion is heavily divided, with shareholders expressing significant disappointment over the valuation and deal structure, leading to active debate regarding the potential for competing bids or the possibility of the agreement being terminated if Tempus shares drop below specific price levels.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market volatility driven by the company's recent FDA approval for its tumor-only diagnostic platform and its strategic acquisition of Personalis, moves that position it to capture a massive oncology market opportunity. While some investors view these developments as long-term bullish catalysts for the platform's AI-driven precision medicine ecosystem, the community remains divided and highly sensitive to the resulting stock dilution and short-term price swings.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending due to the completion of enrollment for its NEXICART-2 trial and the strategic appointment of a new CMO with significant experience in blockbuster biologics, signaling a clear shift toward BLA submission and commercial readiness. Community discussion is heavily focused on the stock's tight tradable float, institutional accumulation by firms like Janus Henderson, and a prevailing sentiment that the asset's 'one-and-done' clinical profile makes it a prime candidate for a strategic buyout by major pharmaceutical companies.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending as investors digest the acquisition of global development rights for the clinical-stage asset safusidenib, reinforcing sentiment around the company's oncology pipeline. The community is actively discussing the stock's significant long-term upside potential, comparing its valuation and pipeline strength to recent high-profile M&A activity in the biotech sector.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is experiencing significant volatility driven by market anticipation of upcoming Section 232 tariff decisions and the potential impact of long-term policy shifts on its domestic manufacturing advantage. While the community is actively debating the company's valuation relative to its reliance on government subsidies and tax credits, the stock remains a central focus for traders navigating the broader energy infrastructure trade as hyperscalers increase demand for reliable power.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Defense, Biotech, and Aerospace Stories Dominate

Markets are opening Thursday with a mix of defense innovation, biotech progress, aerospace supply chain momentum, and turnaround earnings, highlighting how technology and strategic manufacturing continue to drive investor attention across several sectors. From next-generation biomaterials to counter-drone systems and aerospace electronics, the latest corporate developments suggest continued capital flow toward industries tied to national security, healthcare innovation, and advanced manufacturing. $KBLB, $IBO, $GXAI, $MOBX, $BTAI, $ALTO

Why Did IBO Stock Surge 65% In Pre-Market Today?

Equity

The company announced amendments to agreements related to its planned merger with Dr. Ashley's, including extending the deadline to complete the merger to July 1, 2026.

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The firm focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological and immune related diseases. It is also involved in developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The company was founded on October 16, 2018 and is headquartered in Houston, TX.

Impact BioMedical Inc.

Neutral Sentiment

Investment platforms / apps

Social media

Financial media 

Artificial Intelligence

Where do you usually get information about ETFs? 
 
*Sponsored by Calamos and S&amp;P Global

Stocktwits

Where do you usually get information about ETFs? 
 
*Sponsored by Calamos and S&P Global

Current Price	$0.4514
Prev Close	$0.456
Open	$0.4633
Dividend Yield	0.00%
50-Day Moving Average	$0.5267
Beta	-10.13
Avg. Volume	86,488.06
PE Ratio	-0.36

52-Week High	$0.83
52-Week Low	$0.37
Market Capitalization	$49.17M
EPS (Annual)	-$0.3752
Price to Book	4.29
Revenue Per Employee	$4,000.00

Feed

News

Sentiment

Fundamentals

Info

IBOImpact BioMedical Inc.

Latest IBO News